Acute Myelogenous Lymphoma (AML)

**Advanced Disease**
- Matched Related or Unrelated Donor
- Matched Related Donor

**First (CR1) or Higher Remission**
- Matched Related Donor

**BMT345**
- Phase II
- JSP191
- +/- Reduced Conditioning Regimen in Low Dose RT & Fludarabine in MDS/AML Undergoing HCT
  - PI: Muffy Jasper Therapeutics

**BMT342**
- Phase II/III
- to Identify Novel Intervention to Alleviate Morbidity & Mortality After Allogeneic HCT
  - PI: Muffy Fred Hutchinson

**BMT343**
- Phase I/II
- T-Cell Depleted Graft + Conventional & Regulatory T Cells in Advanced Hematologic Malignancies
  - PI: Meyer Orca Biosystems

**BMT346**
- Phase I/II
- MAHCT w/ T Cell Depleted Graft w/ Infusion of Conventional and Regulatory T Cells
  - PI: Meyer NIH

**BMT340**
- Phase III
- Tacrolimus/ Methotrexate vs Cyclophosphamide/ Tacrolimus/ Mycophenolate Mofetil in PBSCRT
  - PI: Rezvani BMT CTN

**BMT339**
- Phase I
- Donor Grafts Derived From OrcaGraft w/ GVHD Prophylaxis in MA-alloHCT in Hematologic Malignancies
  - PI: Meyer Orca Biosystems

**BMT338**
- Phase II
- Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory T-Cell Infusion in MDS&AL
  - PI: Lowsky Stanford

**BMT369**
- Phase II
- MGTA-145 in Combination with Plenixafor in Hematological Malignancies
  - PI: Rezvani Gamida Cell

**BMT333_EXP**
- Phase III
- Expanded Access Omidubicel in Allogeneic Transplantation in Hematological Malignancies
  - PI: Rezvani Gamida Cell

---

**KEY**
- Pending
- Open for Enrollment
- Observation Study
- Optional Path
- Link
- Trial Posting
- Extension Study
- Immunotherapy